Allogene Therapeutics (ALLO) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.13
- Estimate
- -$0.15
- Surprise
- +12.2%
- Revenue (period 2026-06-30)
- $4.6M
- Score today
- 4.8/10
Revenue source: xbrl.
How the report landed
Allogene Therapeutics (ALLO) reported a narrower loss than forecast — diluted EPS of -$0.13 against the -$0.15 estimate (a 12.2% beat on a still-unprofitable quarter).
Coverage in the report window
- Allogene Therapeutics Files Prospectus For $500M Offering — benzinga, 2026-08-12
- Allogene Therapeutics Q2 EPS $(0.13) Beats $(0.17) Estimate, Sales $4.640M Beat $2.222K Estimate — benzinga, 2026-08-12
Where TrendMatrix's rating stands now
TrendMatrix currently rates ALLO Sell at 4.8/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's +12.2% surprise compares with a +17.8% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: lead product candidates (cema-cel, ALLO-316, ALLO-329)
- DATA_ISSUE: analyst_target_implausible (raw $9.00 vs price $2.09 — ratio 4.3×). Rejected, falling back to technical TP.
- Quality below floor (1.8 < 4.0)
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $2.10
- Price target
- $2.19
- Stop
- $1.94
- Upside to target
- +4.3%
Model outputs from TrendMatrix’s engine as of 2026-08-23 — shown for context, not personalized investment advice.
ALLO at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $722.1M
- P/E (fwd)
- -3.0
- 52-week range
- $1.04–$4.46
- Off 52-week high
- 52.9%
- RSI (14)
- 64
- Volume vs avg
- 0.73×
- Score today
- 4.8/10